https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43676 Wed 28 Sep 2022 08:09:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45437 Wed 13 Mar 2024 08:08:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50859 Wed 09 Aug 2023 10:13:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55205 Tue 30 Apr 2024 10:50:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43470 4 months (75% mepolizumab; 25% omalizumab, and 25% macrolide) were recruited. Qualitative semi structured interviews were conducted, with interviews thematically analysed. Results: Participants’ mean (SD) age was 59.5 (15.3) years, and 50% were male. Participants reported 4.5 (2.3) exacerbations in the past year. Asthma Control Questionnaire score was 2.0 (1.4). The monoclonal add-on therapies had been prescribed for a median (IQR) of 12.5 (7.0, 24.0) months. Experience was captured in four emergent themes: “Life is just easier” provided an overall message that the add-on therapy made the participants’ life easier in terms of increasing participation, levelling out symptoms, providing more energy and reducing healthcare use. “Prednisone: A necessary evil” was discussed, particularly in terms of dose and dependence and damaging side effects. The theme “worry and hope for the future” referenced treatment non-response or cessation of effect which was discussed by some participants. Finally, “holistic care” was centred on the sentiment that the participant’s asthma management and overall health were not related to one aspect or medication alone. Conclusion: Patients with severe asthma experience vast improvements in quality-of-life and life participation with add-on therapies, but there remains a significant burden related to oral corticosteroids and incomplete treatment responses. Addressing this residual burden is an important area for future research.]]> Tue 20 Sep 2022 10:13:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51001 Tue 15 Aug 2023 12:06:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44349 Tue 11 Oct 2022 19:35:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45193 Thu 27 Oct 2022 14:56:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48885 10 years: 65% vs. 33%, p < 0.002). QoL was impaired in both groups, but there were no significant differences between severe asthma and COPD carers in either of the SF-12 component scores. The HADS scores revealed no difference between groups. Compared to severe asthma carers, COPD carers had significantly greater needs for: ‘having time for self’ (33% vs. 13%, p = 0.006), ‘equipment to help care for relative’ (33% vs. 13%, p = 0.006), ‘practical help in the home’ (35% vs. 18%, p = 0.006) and ‘getting a break from caring overnight’ (21% vs. 6%, p = 0.023). Conclusion: QoL is impaired in carers of people with severe asthma to a similar degree of COPD carers and other debilitating diseases like cancer. These novel data highlight the support needs of severe asthma carers and identifies areas where tailored support is needed to reduce their substantial carer burden.]]> Thu 20 Apr 2023 09:27:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33707 Thu 13 Jan 2022 10:32:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47317 Thu 06 Jul 2023 13:59:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32622 Thu 03 Feb 2022 12:18:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46274 Mon 14 Nov 2022 15:28:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44178 Mon 10 Oct 2022 10:20:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40572 Mon 08 Aug 2022 15:11:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36441 Mon 04 May 2020 13:05:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55351 r > –0.19; P ≤ .03). Conclusions: Adults with severe asthma have worse core function than their control counterparts, independent of sex. Furthermore, as core function decreases, breathing symptoms increase.]]> Fri 17 May 2024 15:58:53 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51535 Fri 08 Sep 2023 12:31:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36583 Fri 01 Apr 2022 09:23:30 AEDT ]]>